ERBB2 and breast carcinoma: The NALA phase III trial studied 621 patients with metastatic HER2-positive breast cancer who had received more than two previous HER2-directed therapies, and randomized them to treatment with neratinib plus capecitabine (N + C) versus lapatinib with capecitabine (L + C).